The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×

“Ms. A” was a 30-year-old married Hispanic woman with four children who had a diagnosis of schizoaffective disorder. Her history was significant for multiple psychiatric hospitalizations, including one in her early 20s, one shortly after the birth of her third child, and four recent admissions for symptoms of mood instability, auditory hallucinations, agitation, suicidal ideation, and threats of harming her children and husband. On multiple occasions, Ms. A was brought to the emergency department by the police after her husband reported that she was feeling suicidal, homicidal, and paranoid. The Department of Children and Family Services had been contacted because of concern about the safety of the children.

Ms. A’s treatment history included pharmacotherapy with fluoxetine, paroxetine, haloperidol, risperidone, olanzapine, fluphenazine, and propranolol. She reported that haloperidol caused fatigue, restlessness, and difficulty thinking. She had also been treated with haloperidol decanoate because of poor medication adherence. Her past history was significant for a suicide attempt with an overdose of “protein pills” while pregnant with her third child.

After her most recent psychiatric hospitalization, Ms. A was followed in an outpatient rehabilitation clinic by a multimodal treatment team that met weekly and included a second-year psychiatry resident (Dr. P), an attending psychiatrist, a psychologist (Dr. M), and a nurse. As a resident, Dr. P had the responsibility of formulating and documenting treatment decisions regarding patient care and informing the attending psychiatrist, with whom he met on a weekly basis for individual supervision, of these decisions.

Ms. A continued to display symptoms of hypomania, disorganization, and difficulty managing her children. Dr. P obtained a consultation from a Spanish-speaking attending who determined that Ms. A’s ability to comprehend English was sufficient for communication about her ongoing care and recommended treatment with either valproic acid or lithium. Because of the atypical features of her illness, Dr. P selected valproic acid. After discussing the risks, including teratogenicity, with Ms. A and documenting a discussion of the risks in the medical record, Dr. P started her on valproic acid. Her other medications included fluoxetine 20 mg, risperidone 4 mg, and a transdermal contraceptive patch (ethinyl estradiol and norelgestromin), which Ms. A had been on for over a year. Dr. M discussed the importance of not getting pregnant with both Ms. A and her husband and arranged for Ms. A’s ongoing care in an obstetrics/gynecology clinic.

Two weeks after starting valproic acid, Ms. A reported missing her menstrual period. A stat pregnancy test was negative, and valproic acid was gradually titrated to 2500 mg/day. Over the next few months, Ms. A remained stable, without hospitalization. She told Dr. M that she was able to care for and enjoy time with her children, and she did not want to have any more children for at least 3 years. Ms. A was adherent to her treatment and saw her therapist every week and her outpatient psychiatrist every 2 to 4 weeks.

Four and a half months later, Ms. A again reported to her psychiatrist that she had missed her menstrual period. Dr. P instructed her to obtain a pregnancy test right away, but Ms. A stated that she wanted to take a home pregnancy test. Two days later, she told Dr. M that the results of the home pregnancy test were unclear. She was again instructed to go to the lab to obtain a pregnancy test. Five days later, Dr. P obtained the results, which indicated that the pregnancy test was positive. He was unable to reach Ms. A for 2 days before he could inform her of the results and instruct her to stop taking valproic acid, 9 days after she reported the missed menstrual period.

Ms. A relapsed 6 weeks after discontinuing valproic acid and was hospitalized after taking an overdose of risperidone in an attempt to harm herself and her fetus. During her hospitalization, she was started on lithium, which she remained on for the duration of the pregnancy. An ultrasound examination was performed at 24 weeks’ gestation; findings were consistent with a neural tube defect and ventriculomegaly. Maternal-fetal medicine was consulted. The psychiatry resident, psychiatry attending, psychologist, and nurse met with Ms. A and her husband on multiple occasions to assess and discuss their understanding of the ultrasound results, the baby’s diagnosis, and Ms. A’s options regarding the pregnancy and her treatment. The option of a therapeutic abortion was discussed and declined by Ms. A and her husband. The baby was born at 38 weeks’ gestation with a birth weight of 8 pounds 14 ounces and Apgar scores of 9 and 9. He was diagnosed with spina bifida with hydrocephalus, lumbar region, and Chiari malformation type II.

This case resulted in a lawsuit that went to trial 12 years after the baby was born. Reasons for the delay are not known. Contentions raised by the plaintiff included the following: 1) valproate was a “dangerous” medication because of its teratogenic potential and lithium was a safer alternative; 2) the medical record lacked documentation by the attending psychiatrist of both the risk of teratogenicity and communication with the patient about the risks from valproic acid; 3) valproic acid treatment should not have been continued after Ms. A’s first missed menstrual period; 4) the monitoring of Ms. A’s birth control and her ongoing ability to correctly use the hormonal patch was inadequate; 5) supervision of the resident by the attending psychiatrist regarding handling of the second missed menstrual period was lacking; 6) valproic acid should have been discontinued immediately upon learning of Ms. A’s second missed menstrual period and the possibility of a pregnancy. The trial resulted in a plaintiff’s verdict of $18 million, substantially less than the $50 million the plaintiff had asked of the jury.

The concept of standard of care in medicine has evolved over decades to include a legal definition of clinical care that is consistent with what a reasonable practitioner in the community would provide. In treating women of childbearing age who suffer from moderate to severe psychopathology, clinicians face challenging decisions, as they must consider the health and welfare of both the mother and the unborn child if the patient becomes pregnant. This case illustrates a difficult clinical situation in which, in our judgment, the treating clinicians provided treatment that met the standard of care. And yet the jury in the civil malpractice trial felt differently and awarded a substantial amount of money to the plaintiffs. How can we understand this verdict?

First, the distinction between optimal or “perfect” care and standard of care must be considered. Implicit in its definition is that the standard of care does not require either perfect care or the care that would be provided by an expert in the field. For the standard of care to be met simply requires that the threshold of reasonable care is provided. In this case, Dr. P provided a reasonable standard of care. The patient had severe schizoaffective disorder with multiple hospitalizations, was markedly dysfunctional and was a risk to herself and her family when ill, and had not responded optimally to many psychotropic medications in the past. Although other options, such as lithium, could have been considered, valproate was a reasonable alternative. (The atypical/schizoaffective features would predict a less than optimal response to lithium in this situation [1].) The patient was using an appropriate form of birth control—hormonal contraceptive patches (placing her risk of a pregnancy with a baby with a neural tube defect at less than 0.05%)—and she made it clear that she did not want to become pregnant during the next several years. Dr. P clearly informed the patient, on multiple occasions, of the teratogenic risk of valproate and documented these discussions in the chart. These warnings were repeated by Dr. M, the patient’s psychologist. The patient was capable of giving informed consent and understood the discussion. When the patient’s period was late the first time, Dr. P appropriately requested a pregnancy test, which was negative. Later, when Ms. A missed her period again, Dr. P again appropriately requested a pregnancy test, which the patient did not get in a timely manner. Despite urging by the treatment team for the test, it was 9 days until Ms. A finally got the result of the pregnancy test, which was positive, whereupon Dr. P appropriately discontinued the valproate immediately. Later, when an ultrasound examination revealed the presence of spina bifida in the fetus, Ms. A had multiple discussions with various members of her care team regarding her situation, including the option of terminating the pregnancy. Partly because of pressure from her husband, she declined a therapeutic abortion. She later gave birth to an infant with spina bifida and multiple other abnormalities.

This summary of events reflects thoughtful, involved, appropriate care of a woman with a severe psychiatric disorder, which seems to have met the standard of care despite the negative outcome of a disabled child. Yet the care was not perfect. While some clinicians may have made other treatment decisions, such as instructing discontinuation of valproic acid upon learning of a missed menstrual cycle or recommending two different types of contraception before prescribing valproic acid, Dr. P’s care was “reasonable,” falling within community standards. At a number of junctures, as was highlighted at the trial by the plaintiff’s expert witnesses, the care and the documentation of the care could have been different and probably better. As a resident, Dr. P did not discuss the initial prescription of the valproate with his attending faculty member; at that time, there was no documentation (and possibly no discussion) of alternative treatments, such as lithium. When Ms. A first missed her menstrual period and thought she was pregnant despite being on a reliable transdermal patch, Dr. P and the attending could have had a discussion with the patient to assess her thought process. Although the pregnancy test was negative, the missed menstrual cycle presented an opportunity for further clarification of Ms. A’s risks and an understanding of any possible mixed feelings regarding a pregnancy. When Ms. A missed her period a second time, Dr. P appropriately told her to obtain a pregnancy test. Yet he did not discontinue the valproate until the test results were returned. (It may be presumed that Dr. P assumed that the missed period did not reflect a pregnancy, as had occurred 6 months previously.) He did not walk her to the laboratory for the pregnancy test. Although Dr. M, the patient’s psychologist, also urged the patient to obtain the pregnancy test, Dr. P did not call the patient to more urgently remind her to get the test. Thus, the fetus was exposed to 9 extra days of valproate until the pregnancy test results were returned. (Whether this delay in discontinuing the valproate would have made a difference in the outcome is unclear. At trial, the two sides’ experts disagreed on whether the spinal cord defect would already have occurred at the time that Ms. A first noted her missed period.)

Complicating this case are the unclear boundaries inherent in a teaching institution. In this case, the responsibility of a psychiatric resident and the attending physician was, as is commonly the case, shared and, as a result, vague. Should it have been required that the attending faculty member be consulted before the valproate was prescribed? The attending knew about Dr. P’s decision later and seemingly did not object, but no note documented that discussion. Should the attending faculty member have been required to see the patient directly and then to document that visit and an opinion in the chart? Since the attending physician was aware of the valproate prescription later and did not change the treatment plan, it seems unlikely that the outcome would have differed if the attending psychiatrist had been more involved earlier. Thus, the outcome would not differ but the documentation would have been strengthened; however, the lack of documentation by the attending did affect the outcome of the trial. In a trial, “if it’s not documented, it never happened.” Although the resident did receive weekly supervision from the attending, it was not documented, leading to a false but difficult-to-refute impression of attending noninvolvement. The attending was aware of the resident’s handling of the second missed menstrual period, and if he had documented their discussion, thought process, and treatment plan in the medical record, it would have been beneficial at trial. This case suggests that it may be reasonable for training programs to set guidelines for attendings with regard to documentation of resident supervision and joint decision making. Furthermore, to minimize the risks of an adverse outcome, it seems prudent for major clinical decisions to occur in conjunction with the attending physician rather than in consultation with the attending after the fact.

It must also be acknowledged that different training programs have differing methods of dividing responsibilities between residents and attendings. Thus, no one national standard can be applied. Even within a single academic medical center, different clinics may have different standards, such that attending faculty in some clinics may see every patient at every visit for the entire visit (direct supervision), or for a portion of the visit, whereas in other settings (e.g., psychotherapy clinics), attending faculty supervise residents but do not see the patients directly. Dr. P’s supervision was asynchronous, occurring at a time that was detached from actual patient care. Currently, no national consensus on or standard for the structure of resident supervision in training institutions exists; perhaps uniformity for trainee supervision should be considered by the Residency Review Committee of the Accreditation Council for Graduate Medical Education. Factors to consider for standardization include how frequently attending supervision should occur (weekly? twice weekly?) and what type of documentation is reasonable. If the attending in this case had co-signed the resident’s note with the statement, “I have seen the patient with the resident and agree with the treatment plan that we discussed and jointly formulated,” would the outcome of the trial been affected?

Another conceptual issue raised at trial was the responsibility of the patient in contrast to that of the psychiatric treatment team. As one example, even though the patient was using a hormonal contraceptive patch, should the psychiatric treatment team have trusted that she was capable of using this method reliably? In treating a patient with a psychotic disorder, should we as psychiatrists be responsible for monitoring the patient’s adherence—or even capacity for adherence—to birth control methods that we do not prescribe? Despite the patient’s clear statements that she did not want to become pregnant in the near future, should this be considered before prescribing a teratogenic medication to a woman of childbearing age? In such cases it may be prudent at least to communicate concerns about birth control adherence with the patient’s obstetrician-gynecologist and encourage more frequent follow-ups.

The jury was clearly swayed by some combination of the imperfections in the patient’s care and, in all likelihood, sympathy for a psychiatrically ill woman caring for a severely developmentally disabled child. We cannot know how much of the verdict reflected sympathy and how much a critique of the psychiatric care she received, but both components assuredly contributed to the outcome. The sympathy factor is of course impossible to control and may overcome the strength of reasonable care that may have been provided. The lack of documentation by the attending psychiatrist in this case also had a significant impact on the outcome of the trial. Although the attending psychiatrist was involved in the decision making, the jury may have believed that the patient’s care was left solely up to the resident.

This case also highlights the significant risks associated with the use of valproic acid in pregnancy. These risks include spina bifida, developmental delay, atrial septal defect, cleft palate, hypospadias, polydactyly, craniosynostosis, and autism spectrum disorder (2, 3). At the time of this case, over 900,000 prescriptions of valproic acid were written annually for women between the ages of 15 and 44 (4). However, given the increased risk of significant adverse outcomes for the fetus, the use of valproic acid in women of childbearing age should be minimized. Furthermore, since nearly half of all pregnancies are unplanned (5), clinicians should routinely consider the possibility of an unplanned pregnancy when prescribing valproic acid to women of childbearing potential.

Complex cases sometimes go to trial. In this case, the plaintiff’s verdict was much less than what was asked. Although a jury may not be sophisticated enough to understand the complexity of psychiatric and medical issues, some cases may need to go to trial to defend against excessive settlement demands and verdicts. However, in cases that require an understanding of the challenges and subtleties of psychiatric care, a bench trial, in which the case is decided by a judge, without the assistance of a jury, may be warranted. When a lawsuit is filed, the plaintiff usually has the choice of a jury or a bench trial. Because juries are more likely to be influenced by a preponderance of evidence rather than burden of proof, are often swayed by a compelling story, and often grant larger awards, plaintiffs usually select a jury trial; therefore, most medical malpractice cases are decided by juries.

The overriding lesson in this case is that providing standard-of-care treatment may not be enough to prevent an adverse verdict in a malpractice case. As the cliché goes, bad cases make bad law. Therefore, we should be cautious about overinterpreting the results of this one case to change how we provide care, especially in an academic setting, in which issues of supervisory oversight are simultaneously amorphous and central. Yet, in high-risk cases—very ill psychiatric patients treated with medications in situations (e.g., childbearing age in a female patient) where there is substantial risk in both treating and not treating—special care should be taken to provide both optimal treatment and to document the thought processes underlying that treatment. For women of childbearing potential, the risk of an unplanned pregnancy needs to be considered. This case should, however, remind us of the uncertain outcome of difficult clinical cases, the risk of adverse outcomes, and the complexities of the legal system.

Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at University of California Los Angeles, Los Angeles (Suri, Gitlin); Hughes Socol Piers Resnick & Dym, Ltd., Chicago (Socol).
Send correspondence to Dr. Suri ().

The authors report no financial relationships with commercial interests.

References

1 Pfennig A, Schlattmann P, Alda M, et al.: Influence of atypical features on the quality of prophylactic effectiveness of long-term lithium treatment in bipolar disorders. Bipolar Disord 2010; 12:390–396Crossref, MedlineGoogle Scholar

2 Meador KJ, Baker GA, Browning N, et al.: Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurol 2013; 12:244–252Crossref, MedlineGoogle Scholar

3 Weston J, Bromley R, Jackson CF, et al.: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child. Cochrane Database Syst Rev 2016; 11:CD010224MedlineGoogle Scholar

4 Meador KJ, Loring DW: Risks of in utero exposure to valproate. JAMA 2013; 309:1730–1731Crossref, MedlineGoogle Scholar

5 Finer LB, Zolna MR: Declines in unintended pregnancy in the United States, 2008–2011. N Engl J Med 2016; 374:843–852Crossref, MedlineGoogle Scholar